

Workshop Program 2023





Event Brief

BRG will hold its 340B Industry Roundtable Workshop in person on May 23–24, 2023, at The Madison Hotel in Washington, DC. We have designed this exclusive members-only event with the current and future state of the 340B Drug Pricing Program in mind. During this two-day program, attendees will have the opportunity to network and collaborate with other leading industry stakeholders on a variety of 340B-related themes.

Attendees will benefit from:

- Member-driven discussions on prevailing 340B topics
- Access to leading experts across the healthcare industry
- Solutions-oriented discussions proctored by an antitrust attorney
- An exclusive and intimate setting

DISCLOSURE

The mission of the 340B Industry Roundtable is to promote better understanding about operations and developments related to the federal 340B program and enable its members to make more efficient, competitive, and independent business decisions regarding the program in compliance with applicable laws and regulations. All information to be presented in the workshop will be derived from appropriate sources, including information published by third parties/subscription services; publicly available information and reports; and observations and analysis by BRG staff that do not violate any confidentiality obligations BRG owes to its clients and are appropriately aggregated and anonymized.

•	•	•	•
•	•	•	•
•	•	•	•
•	•	•	•

Schedule at a Glance

Tuesday, May 23

12:00 – 1:00 p.m.	Lunch and Networking
1:00 – 2:00 p.m.	<i>Current State of 340B: Legal and Regulatory Perspectives</i> (featuring John Shakow of King & Spalding)
2:00 – 3:00 p.m.	<i>Current State of 340B: Political and Legislative Perspectives</i> (featuring Dan Todd of Todd Strategy Group)
3:00 – 3:30 p.m.	Networking Break
3:30 – 5:00 p.m.	<i>The Drivers of 340B Growth: Case Studies</i>
5:30 – 6:30 p.m.	Cocktail Reception
6:30 – 8:00 p.m.	Dinner

Wednesday, May 24


8:00 – 9:00 a.m.	Breakfast and Networking
9:00 – 10:00 a.m.	<i>Contract Pharmacy: Where Do We Go from Here?</i>
10:00 – 11:00 a.m.	<i>Confronting 340B Myths with Facts</i>
11:00 – 11:30 a.m.	Networking Break
11:30 a.m. – 12:30 p.m.	<i>The IRA and 340B</i>
12:30 – 1:30 p.m.	Lunch and Networking



Agenda

Tuesday, May 23

12:00 – 1:00 p.m.	Lunch and Networking
1:00 – 2:00 p.m.	Current State of 340B: Legal Perspectives In this session, John Shakow of the law firm King & Spalding will provide an overview of important 340B issues through a legal and regulatory lens, including: <ul style="list-style-type: none">- Federal and Arkansas litigation regarding manufacturer distribution obligations- South Carolina litigation regarding patient definition (<i>Genesis</i>)- Takings, the Constitution, and the future of 340B
2:00 – 3:00 p.m.	Current State of 340B: Political Perspectives In this session, Dan Todd of Todd Strategy Group will share insights into the political landscape surrounding 340B, including perspectives on the likelihood of future legislative activity at the federal and state levels.
3:00 – 3:30 p.m.	Networking Break
3:30 – 5:00 p.m.	The Drivers of 340B Growth: Case Studies Using case studies of several health systems based on publicly available information, this session will explore how covered entities have grown their 340B programs in both traditional and unexpected ways, including through referral networks, expanded interpretation of the patient definition, and formal practice acquisitions. The discussion will highlight implications for future growth in the program and why continued focus on 340B by policymakers and stakeholders remains critical.
5:30–6:30 p.m.	Cocktail Reception
6:30–8:00 p.m.	Dinner



Agenda *(cont.)*

Wednesday, May 24

8:00 – 9:00 a.m. Breakfast and Networking

9:00 – 10:00 a.m. Contract Pharmacy: Where Do We Go from Here?

Since the summer of 2020, more than twenty manufacturers have publicly announced novel 340B distribution models, with implications for various types of stakeholders within the pharmaceutical supply chain. In this session, we will provide an update on stakeholder impact and responses to date. The discussion will include perspectives on recent legal decisions and what may lie ahead.

10:00 – 11:00 a.m. Confronting 340B Myths with Facts

The lack of transparency around the 340B program has created an environment in which myths proliferate about the program and its impact. In this session, we will explore and debunk certain myths, including:

- The 340B program costs taxpayers nothing
- Only nonprofit healthcare providers benefit from 340B
- 340B helps only low-income and underserved communities

We will brainstorm ways members might individually counteract these myths and disseminate facts about 340B based on objective research.


11:00 – 11:30 a.m. Networking Break

**11:30 a.m.–
12:30 p.m. The IRA and 340B**

The Inflation Reduction Act (IRA), signed into law in August 2022, contains important provisions related to pharmaceuticals—all of which have potential implications for the 340B program—including:

- A requirement that manufacturers negotiate drug prices with CMS
- New penalties for increasing the price of Medicare Part B and D drugs at a rate faster than inflation
- Medicare Part D benefit redesign

We will dive deep into each provision and provide perspectives on the impact to different types of stakeholders in the context of 340B. Discussion will include what manufacturers may want to independently consider to prepare for the full implementation of the IRA.





About BRG

Berkeley Research Group, LLC (BRG) is a global consulting firm that helps leading organizations advance in three key areas: disputes and investigations, corporate finance, and performance improvement and advisory. Headquartered in California with offices around the world, we are an integrated group of experts, industry leaders, academics, data scientists, and professionals working across borders and disciplines. We harness our collective expertise to deliver the inspired insights and practical strategies our clients need to stay ahead of what's next.

THINKBRG.COM